(Q50787074)

19 March 2018

title

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. (English)

1 reference

19 March 2018

8

Anthony V D'Amico

1 reference

19 March 2018

author name string

Jason A Efstathiou

1

1 reference

19 March 2018

Ming-Hui Chen

2

1 reference

19 March 2018

William J Catalona

3

1 reference

19 March 2018

David G McLeod

4

1 reference

19 March 2018

Peter R Carroll

5

1 reference

19 March 2018

Judd W Moul

6

1 reference

19 March 2018

Kimberly A Roehl

7

1 reference

19 March 2018

language of work or name

English

0 references

publication date

1 August 2006

1 reference

19 March 2018

published in

Urology

1 reference

19 March 2018

volume

68

1 reference

19 March 2018

issue

2

1 reference

19 March 2018

page(s)

342-347

1 reference

19 March 2018

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Evidence to support a continued stage migration and decrease in prostate cancer specific mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Patterns of practice in the United States: insights from CaPSURE on prostate cancer management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Using prostate-specific antigen to eliminate the staging radionuclide bone scan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

The science of early detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

National practice patterns and time trends in androgen ablation for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Time course and predictors of symptoms after primary prostate cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.02.030

10.1016/J.UROLOGY.2006.02.030

7 January 2021

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018